Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Study Details
Study Description
Brief Summary
This phase II trial studies how well cabazitaxel and prednisone work in treating patients with hormone-resistant prostate cancer that has spread to other parts of the body. Drugs used in chemotherapy, such as cabazitaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 2 |
Detailed Description
PRIMARY OBJECTIVES:
- To test whether men with a poor initial response to androgen deprivation therapy (ADT) have a better front line therapeutic response to cabazitaxel as compared to historical controls of frontline metastatic castrate resistant prostate cancer (CRPC) therapy with abiraterone or enzalutamide.
SECONDARY OBJECTIVES:
-
To determine the Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 response rate, progression free survival (PFS) by Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria, and overall survival (OS).
-
To evaluate safety and toxicity profile of cabazitaxel in patients with CRPC.
TERTIARY OBJECTIVES:
- To collect serum and tumor tissue samples for molecular markers or signature predictive of cabazitaxel benefit (to include status of androgen receptor [AR] pathway, androgen biosynthetic pathway genes, adenosine triphosphate [ATP]-binding cassette sub-family B member 1 [ABCBI], multidrug resistance-associated protein 1 [MRP1], and other mediators of taxane resistance).
OUTLINE:
Patients receive cabazitaxel intravenously (IV) over 1 hour on day 1 and prednisone orally (PO) twice daily (BID) on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Treatment (cabazitaxel, prednisone) Patients receive cabazitaxel IV over 1 hour on day 1 and prednisone PO BID on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. |
Drug: Cabazitaxel
Given IV
Other Names:
Drug: Prednisone
Given PO
Other Names:
|
Outcome Measures
Primary Outcome Measures
- PSA Response Rate, Defined as >= 50% Decline in PSA From Baseline Maintained for at Least 3 Weeks and Measured by the Same Laboratory, and Without Evidence of Other Disease Progression Documented at Time of Confirmatory Values [Up to 18 months.]
The response rate will be compared to a historical response rate of 20% using the exact binomial test for a single proportion. Confidence intervals for the response rate will be calculated using Wilson's method.
Secondary Outcome Measures
- Incidence of Adverse Events, Serious Adverse Events, and Discontinuations, Described and Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 [Up to 28 days after discontinuation of study drug]
Incidence of adverse events, serious adverse events, and discontinuations, described and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03
- Overall Survival (OS) Defined as the Time Interval From the Date of Enrollment to the Date of Death Due to Any Cause. [Up to 18 months.]
Confidence intervals for the response rate will be calculated using Wilson's method. Medians will be estimated using the method of Kaplan and Meier, with confidence intervals estimated using Greenwood's method.
- Progression-free Survival (PFS) Defined as the Time Interval Between the Date of Enrollment and the Date of the First Documentation by the Prostate Cancer Working Group 2 (PCWG2) Criteria. [Approximately 5 months.]
Confidence intervals for the response rate will be calculated using Wilson's method. Medians will be estimated using the method of Kaplan and Meier, with confidence intervals estimated using Greenwood's method.
- Response Evaluation Criteria in Solid Tumors (RECIST) Response Defined as Radiographic Disease Progression [Approximately 5 months.]
Confidence intervals for the response rate will be calculated using Wilson's method. Medians will be estimated using the method of Kaplan and Meier, with confidence intervals estimated using Greenwood's method.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Histologically confirmed prostate adenocarcinoma
-
Metastatic disease
-
Able and willing to provide informed consent and to comply with the study procedures
-
Castration resistant disease defined as evidence of radiological and/or prostate specific antigen (PSA) progression despite castrate levels of testosterone (serum testosterone < 50 ng/dL [1.7 nmol/L]); for PSA progression, there must be at least 2 sequential rises at a minimum of 1-week intervals; the first PSA value must be >= 4 (Prostate Cancer Working Group 2 [PCWG2] criteria)
-
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
-
At least 21 days have passed since completing radiotherapy (exception for radiotherapy: at least 7 days since completing a single fraction of =< 800 cGy to a restricted field or limited-field radiotherapy to non-marrow bearing area such as an extremity or orbit) at the time of registration
-
At least 21 days have passed since receiving any investigational agent at the time of registration
-
At least 21 days have passed since major surgery
-
Neuropathy =< grade 1 at the time of registration
-
Has recovered from all therapy-related toxicity to =< grade 2 (except alopecia, anemia and any signs or symptoms of androgen deprivation therapy) at the time of registration
-
Poor prognosis disease as defined by any of the following:
-
PSA nadir >=4.0, or
-
Gleason score 8-10, or
-
Time from ADT initiation to CRPC of =< 16 months
-
Hemoglobin >= 90 g/L
-
Neutrophils >= 1.5 x 10^9 /L
-
Platelets >= 100 x 10^9/L
-
Aspartate aminotransferase (AST) < 1.5 x upper limit of normal (ULN)
-
Alanine aminotransferase (ALT) < 1.5 x ULN
-
Bilirubin =< 1.0 x ULN (exceptions for Gilbert's syndrome)
-
Creatinine =< 1.5 x ULN
Exclusion Criteria:
-
Prior therapy with cabazitaxel or to other drugs formulated with polysorbate 80
-
Prior taxanes for CRPC
-
Prior enzalutamide, abiraterone or ketoconazole
-
Other condition, illness, psychiatric condition, or laboratory abnormality that may increase the risk associated with administration of cabazitaxel, study participation, or may interfere with the interpretation of study results and in the judgment of the investigator would make the patient inappropriate for entry into this study
-
Histologic evidence of small cell/neuroendocrine prostate cancer
-
Patients with reproductive potential who do not agree to use accepted and effective method of contraception during the study treatment period and up to 6 months after the last administered dose; the definition of "effective method of contraception" will be based on the investigator's judgment
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | University of California Davis Comprehensive Cancer Center | Sacramento | California | United States | 95817 |
Sponsors and Collaborators
- University of California, Davis
- Sanofi
Investigators
- Principal Investigator: Christopher Evans, University of California, Davis
Study Documents (Full-Text)
More Information
Publications
None provided.- 868922
- UCDCC#261
- UCDCC#261
- NCI-2016-00961
Study Results
Participant Flow
Recruitment Details | |
---|---|
Pre-assignment Detail |
Arm/Group Title | Treatment (Cabazitaxel, Prednisone) |
---|---|
Arm/Group Description | Patients receive cabazitaxel IV over 1 hour on day 1 and prednisone PO BID on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cabazitaxel: Given IV Prednisone: Given PO |
Period Title: Overall Study | |
STARTED | 2 |
COMPLETED | 2 |
NOT COMPLETED | 0 |
Baseline Characteristics
Arm/Group Title | Treatment (Cabazitaxel, Prednisone) |
---|---|
Arm/Group Description | Patients receive cabazitaxel IV over 1 hour on day 1 and prednisone PO BID on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cabazitaxel: Given IV Prednisone: Given PO |
Overall Participants | 2 |
Age (Count of Participants) | |
<=18 years |
0
0%
|
Between 18 and 65 years |
1
50%
|
>=65 years |
1
50%
|
Sex: Female, Male (Count of Participants) | |
Female |
0
0%
|
Male |
2
100%
|
Ethnicity (NIH/OMB) (Count of Participants) | |
Hispanic or Latino |
0
0%
|
Not Hispanic or Latino |
2
100%
|
Unknown or Not Reported |
0
0%
|
Region of Enrollment (participants) [Number] | |
United States |
2
100%
|
Outcome Measures
Title | PSA Response Rate, Defined as >= 50% Decline in PSA From Baseline Maintained for at Least 3 Weeks and Measured by the Same Laboratory, and Without Evidence of Other Disease Progression Documented at Time of Confirmatory Values |
---|---|
Description | The response rate will be compared to a historical response rate of 20% using the exact binomial test for a single proportion. Confidence intervals for the response rate will be calculated using Wilson's method. |
Time Frame | Up to 18 months. |
Outcome Measure Data
Analysis Population Description |
---|
The study was stopped due to poor accrual, and only 2 patients received study treatment. PSA was collected, but the number of evaluable patients was insufficient to perform analysis of this outcome measure. |
Arm/Group Title | Treatment (Cabazitaxel, Prednisone) |
---|---|
Arm/Group Description | Patients receive cabazitaxel IV over 1 hour on day 1 and prednisone PO BID on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cabazitaxel: Given IV Prednisone: Given PO |
Measure Participants | 2 |
Count of Participants [Participants] |
0
0%
|
Title | Incidence of Adverse Events, Serious Adverse Events, and Discontinuations, Described and Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 |
---|---|
Description | Incidence of adverse events, serious adverse events, and discontinuations, described and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 |
Time Frame | Up to 28 days after discontinuation of study drug |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Treatment (Cabazitaxel, Prednisone) |
---|---|
Arm/Group Description | Patients receive cabazitaxel IV over 1 hour on day 1 and prednisone PO BID on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cabazitaxel: Given IV Prednisone: Given PO |
Measure Participants | 2 |
Back pain |
1
50%
|
Diarrhea |
1
50%
|
Fatigue |
2
100%
|
Hot flashes |
1
50%
|
Neutrophil count decreased |
2
100%
|
Non-cardiac chest pain |
1
50%
|
Pain |
1
50%
|
Renal and urinary disorders - Other, specify |
1
50%
|
White blood cell decreased |
2
100%
|
Title | Overall Survival (OS) Defined as the Time Interval From the Date of Enrollment to the Date of Death Due to Any Cause. |
---|---|
Description | Confidence intervals for the response rate will be calculated using Wilson's method. Medians will be estimated using the method of Kaplan and Meier, with confidence intervals estimated using Greenwood's method. |
Time Frame | Up to 18 months. |
Outcome Measure Data
Analysis Population Description |
---|
Study was terminated prematurely and data was not collected to assess this outcome measure. |
Arm/Group Title | Treatment (Cabazitaxel, Prednisone) |
---|---|
Arm/Group Description | Patients receive cabazitaxel IV over 1 hour on day 1 and prednisone PO BID on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cabazitaxel: Given IV Prednisone: Given PO |
Measure Participants | 0 |
Title | Progression-free Survival (PFS) Defined as the Time Interval Between the Date of Enrollment and the Date of the First Documentation by the Prostate Cancer Working Group 2 (PCWG2) Criteria. |
---|---|
Description | Confidence intervals for the response rate will be calculated using Wilson's method. Medians will be estimated using the method of Kaplan and Meier, with confidence intervals estimated using Greenwood's method. |
Time Frame | Approximately 5 months. |
Outcome Measure Data
Analysis Population Description |
---|
Study was terminated prematurely and insufficient data was collected to assess this outcome measure. |
Arm/Group Title | Treatment (Cabazitaxel, Prednisone) |
---|---|
Arm/Group Description | Patients receive cabazitaxel IV over 1 hour on day 1 and prednisone PO BID on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cabazitaxel: Given IV Prednisone: Given PO |
Measure Participants | 0 |
Title | Response Evaluation Criteria in Solid Tumors (RECIST) Response Defined as Radiographic Disease Progression |
---|---|
Description | Confidence intervals for the response rate will be calculated using Wilson's method. Medians will be estimated using the method of Kaplan and Meier, with confidence intervals estimated using Greenwood's method. |
Time Frame | Approximately 5 months. |
Outcome Measure Data
Analysis Population Description |
---|
Study was terminated prematurely and insufficient data was collected to assess this outcome measure. |
Arm/Group Title | Treatment (Cabazitaxel, Prednisone) |
---|---|
Arm/Group Description | Patients receive cabazitaxel IV over 1 hour on day 1 and prednisone PO BID on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cabazitaxel: Given IV Prednisone: Given PO |
Measure Participants | 0 |
Adverse Events
Time Frame | Up to 28 days after discontinuation of study drug. | |
---|---|---|
Adverse Event Reporting Description | Number of Participants with Adverse Events. | |
Arm/Group Title | Treatment (Cabazitaxel, Prednisone) | |
Arm/Group Description | Patients receive cabazitaxel IV over 1 hour on day 1 and prednisone PO BID on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cabazitaxel: Given IV Prednisone: Given PO | |
All Cause Mortality |
||
Treatment (Cabazitaxel, Prednisone) | ||
Affected / at Risk (%) | # Events | |
Total | 0/2 (0%) | |
Serious Adverse Events |
||
Treatment (Cabazitaxel, Prednisone) | ||
Affected / at Risk (%) | # Events | |
Total | 0/2 (0%) | |
Other (Not Including Serious) Adverse Events |
||
Treatment (Cabazitaxel, Prednisone) | ||
Affected / at Risk (%) | # Events | |
Total | 2/2 (100%) | |
Gastrointestinal disorders | ||
Diarrhea | 1/2 (50%) | |
General disorders | ||
Fatigue | 2/2 (100%) | |
Non-cardiac chest pain | 1/2 (50%) | |
Pain | 1/2 (50%) | |
Investigations | ||
Neutrophil count decreased | 2/2 (100%) | |
White blood cell decreased | 2/2 (100%) | |
Musculoskeletal and connective tissue disorders | ||
Back pain | 1/2 (50%) | |
Nervous system disorders | ||
Headache | 1/2 (50%) | |
Renal and urinary disorders | ||
Renal and urinary disorders - Other, specify | 1/2 (50%) | |
Vascular disorders | ||
Hot flashes | 1/2 (50%) |
Limitations/Caveats
More Information
Certain Agreements
All Principal Investigators ARE employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
Name/Title | Analyst |
---|---|
Organization | University of California, Davis |
Phone | 916-734-8053 |
nlogihara@ucdavis.edu |
- 868922
- UCDCC#261
- UCDCC#261
- NCI-2016-00961